Outcomes of the Novel Supreme Drug-Eluting Stent in Complex Coronary Lesions: A PIONEER III Substudy

Abstract

<h2>Abstract</h2><h3>Background</h3> The Supreme healing-targeted drug-eluting stent (DES) is designed to promote endothelial healing to reduce stent-related adverse events. This may be particularly relevant among complex lesions that have a higher rate of adverse events. We sought to compare 1-year outcomes of percutaneous coronary intervention in complex lesions between the Supreme DES and contemporary durable-polymer, everolimus-eluting stents (DP-EES). <h3>Methods</h3> PIONEER III was a multicenter, prospective, single-blind clinical trial, randomizing 1629 patients with either an acute or chronic coronary syndrome in a 2:1 ratio to the Supreme DES or DP-EES. Complex lesions (American College of Cardiology/American Heart Association type B2/C) were found in 1137 patients. Outcomes were also compared for specific parameters of lesion complexity: severe calcification, long length (>20 ​mm), and severe tortuosity. The primary end point was target lesion failure at 1 ​year. <h3>Results</h3> At 1 ​year, there was no difference in target lesion failure between the Supreme DES and DP-EES: (5.7% vs 5.6%; hazard ratio 1.00, 95% confidence interval 0.59-1.68, <i>P</i> = .99). Similarly, there were no differences in the secondary end points of lesion success (99.7% vs 99.4%, <i>P</i> = .41), device success (97.0% vs 98.5%, <i>P</i> = .14), target vessel failure (6.5% vs 7.4%, <i>P</i> = .50), major adverse cardiac events (7.8% vs 8.5%, <i>P</i> = .64), or stent thrombosis (0.7% vs 1.1%, <i>P</i> = .48). A trend was observed toward a higher rate of target lesion revascularization with the Supreme DES (2.5% vs 0.9%, <i>P</i> = .06). <h3>Conclusions</h3> This study suggests that the Supreme DES is as effective and safe at 1 ​year compared with the standard DP-EES across a broad spectrum of lesion complexity.